Clinical trial
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
NCT04688788
Study timeline
Study start (actual)2021-04-28Date precision: day
Registry last updated2026-08-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Relapsing Remitting Multiple Sclerosisunresolved
Secondary Progressive Multiple Sclerosisunresolved
Primary Progressive Multiple Sclerosisunresolved
Interventions
RituximabDRUG · verified · RxNorm: rituximab
OcrelizumabDRUG · verified · RxNorm: ocrelizumab
FexofenadineDRUG · verified · RxNorm: fexofenadine
ParacetamolDRUG
MethylprednisoloneDRUG · verified · RxNorm: methylprednisolone
Sponsors & collaborators
Copenhagen University Hospital, Rigshospitaletlead sponsor
Odense University Hospitalcollaborator
Aarhus University Hospitalcollaborator
Aalborg University Hospitalcollaborator
Herlev Hospitalcollaborator
Hillerod Hospital, Denmarkcollaborator
Kolding Sygehuscollaborator
Gødstrup Hospitalcollaborator
Hvidovre University Hospitalcollaborator
Hospital of South West Jutland, Esbjerg, Denmarkcollaborator
University of Copenhagencollaborator
Hospital of Southern Jutlandcollaborator
Danske Regionercollaborator
Sanquin Research & Blood Bank Divisionscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04688788 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.